
Rotigotine hydrochloride [Dopamine D2 Receptor; Dopamine D3 Receptor Agonist]
[CAT#: MOD2005ZP234]
Dopamine D2 and D3 receptor agonist
- Target:
- DRD2
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
[2]. Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86.
[3]. Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91.
[4]. Radad K, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP? and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86.
This gene encodes the D2 subtype of the dopamine receptor, which is coupled to the Gi subtype of the G protein-coupled receptor. This G protein-coupled receptor can inhibit the activity of adenylate cyclase.
In mice, the modulation and exploration of D2R surface expression by neurocalcium sensor 1 (NCS-1) in the dentate gyrus is related to synaptic plasticity and memory formation. A recent study showed that D2R has a potential role in restoring forearm cortical fear memory.
In Drosophila, activation of D2 autoreceptors protects dopamine neurons from MPP+-induced cell death, a toxin that mimics the pathology of Parkinson's disease.